Please Enable Images To See This
Biotech Is a Screaming 'Melt Up' Buy Today
By Dr. Steve Sjuggerud
Monday, November 6, 2017
The biotech sector recently fell by 8% in three weeks.

I believe the bust is overdone. And now is a great moment to swoop in and buy...

Biotech was by far the best-performing sector in the last great "Melt Up," when stocks soared at the end of the 1990s bull market. And I expect it will perform well again as today's Melt Up starts to pick up steam...

----------Recommended Links---------
'Finally, a bailout for the rest of us!'
After spending billions to bail out greedy banks, Congress is finally bailing out hardworking citizens who save for retirement. Learn more here.
This New Platform Could Change the Way You Invest
It's the one of the most cost-effective ways to invest in precious metals – and it's revolutionizing the way you buy, sell, and store your metals. See for yourself how you can now get more metal for your money than ever before.
---------------------------------

The main thing most people remember from the great dot-com boom is that tech stocks soared.

But take a look at this chart... It shows that biotech stocks (as measured by the Nasdaq Biotechnology Index) dramatically outperformed tech stocks in the final months of the last great Melt Up.


The iShares Nasdaq Biotechnology Fund (IBB) has had a rough few weeks. It's down 8% from its most recent peak. Importantly, that has pushed biotech stocks to an "oversold extreme."

We measure "overbought" or "oversold" levels with the relative strength index ("RSI") – the typical indicator that tells us when an investment has moved too quickly to the upside or downside.

Last week, the RSI in biotech stocks fell to its second-lowest level in the last 10 years.

That begs the question – what happened after the MOST extreme level in the last 10 years?

Biotech stocks hit their biggest oversold extreme on August 8, 2011. After that, they shot up by more than 40% in just six months. You can see it for yourself in this chart...


Of course, longtime readers know I don't like to buy into a downtrend. I want to wait for the uptrend to confirm my idea before I get in.

Similarly, with the RSI, I don't want to buy when a stock (or fund) is oversold. That tells me it's hated... But the problem is, it can always get a lot more hated!

So I prefer to wait for an uptrend in the RSI, too... to wait for the oversold extreme to go away.

Fortunately, that's what we're seeing today. The oversold extreme appears to be gone in biotech. It looks like the downtrend might be over, and we could be right at the start of an uptrend. This chart shows the details...


This week, our True Wealth Systems computers went against what I'm telling you today. They said to sell biotech – and they're usually right.

But there are times when I disagree with our computers. This is one of those times. I'm willing to go against them today because I believe this is the right setup – one that's giving us a huge opportunity.

You know I'm a strong believer in what I call the Melt Up. And you know that biotech was a dramatic outperformer in the last great Melt Up. I expect biotech will be a great performer in this Melt Up, as well. So this mini-bust in biotech stocks gives us a great entry point...

This might be your last – and best! – chance to get into biotech stocks before they take off in the Melt Up.

Take advantage of it...

Good investing,

Steve
Further Reading:

Steve says biotech stocks are a great way to profit as the bull market enters its final innings. Check out his most recent Melt Up essays here:
 
  Print


NEW HIGHS OF NOTE LAST WEEK
 
Wal-Mart (WMT)... discount retailer
Dollar Tree (DLTR)... dollar stores
C.H. Robinson Worldwide (CHRW)... shipping technology
Apple (AAPL)... iPhones, iPads, and more
Intel (INTC)... semiconductors
Adobe Systems (ADBE)... computer software
Match (MTCH)... online dating
Interactive Brokers (IBKR)... online brokerage
Activision Blizzard (ATVI)... video games
Churchill Downs (CHDN)... horse racing and gambling
Madison Square Garden (MSG)... sports and concerts
Vail Resorts (MTN)... ski resorts
Hyatt Hotels (H)... hotels
Marriott (MAR)... hotels
Fiat Chrysler Automobiles (FCAU)... cars and trucks
Honda Motor (HMC)... cars and trucks
Toyota Motor (TM)... cars and trucks
Royal Dutch Shell (RDS-A)... oil giant
Rayonier (RYN)... timberland
Deere (DE)... tractors and farming equipment
Owens Corning (OC)... roofing and insulation
Consolidated Edison (ED)... utilities
Exelon (EXC)... utilities
Cigna (CI)... health insurance
Becton Dickinson (BDX)... needles and syringes

NEW LOWS OF NOTE LAST WEEK
 
GGP (GGP)... mall REIT
JC Penney (JCP)... retail "old guard"
Nordstrom (JWN)... retail "old guard"
Under Armour (UAA)... sports apparel
CBS (CBS)... television
Viacom (VIAB)... television

This sector could soar triple digits as the Melt Up continues...
 
Biotech stocks aren't the only sector to soar during a Melt Up. Today, it's time to buy in with this fund...
 

Are You a
New Subscriber?

If you have recently subscribed to a Stansberry Research publication and are unsure about why you are receiving the DailyWealth (or any of our other free e-letters), click here for a full explanation...
 

Advertisement

As the Dow approaches 30,000 for the first time ever, millions of investors will make a mistake that could cost them thousands of dollars. If you own stocks, read this urgent warning from a PhD whose work oversees $10 billion.

recent articles

Where's the Biggest Bubble?
By Porter Stansberry
Friday, November 3, 2017
 
Only one kind of financial asset is trading at all-time levels...
 
What Will Cause the Next Crash
By Porter Stansberry
Thursday, November 2, 2017
 
The current bull market is hiding a huge risk...
 
Why Japanese Stocks Could Soar 18% Over the Next Year
By Brett Eversole
Wednesday, November 1, 2017
 
The Japanese stock market finished an incredible streak last week...
 
New Home Sales 'Soaring' and 'Surging,' With More Gains to Come
By Dr. Steve Sjuggerud
Tuesday, October 31, 2017
 
It's Economics 101 – when you have no supply and a ton of demand, prices go higher...
 
Nobody's Throwing Rose Petals at My Feet
By Dr. Steve Sjuggerud
Monday, October 30, 2017
 
"When folks are throwing rose petals at my feet, and I'm too busy to return your phone call, that's my ultimate sell indicator."
 

Home | About Us | Resources | Archive | Free Reports | Privacy Policy
To unsubscribe from DailyWealth and any associated external offers, click here.

Copyright 2017 Stansberry Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This e-letter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry Research, LLC., 1125 N Charles St, Baltimore, MD 21201

LEGAL DISCLAIMER: This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility. Stansberry Research expressly forbids its writers from having a financial interest in any security they recommend to our subscribers. And all Stansberry Research (and affiliated companies) employees and agents must wait 24 hours after an initial trade recommendation is published on the Internet, or 72 hours after a direct mail publication is sent, before acting on that recommendation.

You're receiving this email at newsletter@newslettercollector.com. If you have any questions about your subscription, or would like to change your email settings, please contact Stansberry Research at (888) 261-2693 Monday – Friday between 9:00 AM and 5:00 PM Eastern Time. Or if calling internationally, please call 443-839-0986. Stansberry Research, 1125 N Charles St, Baltimore, MD 21201, USA.

If you wish to contact us, please do not reply to this message but instead go to info@stansberrycustomerservice.com. Replies to this message will not be read or responded to. The law prohibits us from giving individual and personal investment advice. We are unable to respond to emails and phone calls requesting that type of information.